AXSOME THERAPEUTICS, INC. (AXSM) Free cash flow 2016–2025
AXSOME THERAPEUTICS, INC. (AXSM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$93.9MFY2025 · since FY2016: -$21.4M → -$93.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$93.9M | +27.0% |
| FY2024 | -$128.7M | +11.7% |
| FY2023 | -$145.7M | -24.3% |
| FY2022 | -$117.2M | -8.0% |
| FY2021 | -$108.5M | -38.3% |
| FY2020 | -$78.5M | -69.2% |
| FY2019 | -$46.4M | -54.2% |
| FY2018 | -$30.1M | -13.6% |
| FY2017 | -$26.5M | -23.8% |
| FY2016 | -$21.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AXSM financial trends
AXSM RevenueAXSM Net incomeAXSM Net marginAXSM Gross profitAXSM Gross marginAXSM Operating incomeAXSM Operating marginAXSM Operating cash flowAXSM Capital expendituresAXSM Return on equityAXSM Stock buybacksAXSM Dividends paidAXSM Total assetsAXSM Total liabilitiesAXSM Shareholders’ equityAXSM overview →